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Preamble
It is becoming more apparent each day that despite a strong
national commitment to excellence in health care, the re-
sources and personnel are finite . It is, therefore, appropriate
that the medical profession examine the impact of develop-
ing technology on the practice and cost of medical care .
Such analysis, carefully conducted, could potentially impact
on the cost of medical care without diminishing the effec-
tiveness of that care .
To this end, the American College of Cardiology and the
American Heart Association in 1980 established a Task
Force on Assessment of Diagnostic and Therapeutic Cardio-
vascular Procedures with the following charge :
The Task Force of the American College of Cardiology and
the American Heart Association shall define the role of
specific noninvasive and invasive procedures in the diag .
nuns and management of cardiovascular disease .
The Task Force shall address, when appropriate, the contri .
bmion, uniqueness, sensitivity . specificity, indications,
Address for reorinls Mr . David I . Ftild, Assonale Executive Vice
President, American College of Cardiology, 9111 Old Gcorgelown Road,
aclhesda, Marylend 20814 .
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contraindications and cost-effectiveness of such specific
procedures .
The Task Force shall include a Chairman and four members,
two representatives from the American Heart Association
and two representatives from the American College of
Cardiology. The Task Force may select ad hoc members
as needed upon the approval of the Presidents of both
organioations. Recommendations of the Task Farce em
forwarded to the President of each organization .
The members of the Task Force are : Roman W . De-
Sanctis, MD, Harold T . Dodge, MD, T . Joseph Reeves, MD,
Sylvan Lee Weinberg, MD and Charles Fisch, MD, Chair-
man.
The Subcommittee on Peecutaeeous Transluminal Coro-
nary Angioplasty was chaired by Thomas J . Ryan, MD, and
included the following members : David P. Faxon, MD, Rolf
M . Gunnar, MD, J . Ward Kennedy, MD, Spencer B . King
111, MD, Floyd D. Loop, MD, Kirk L . Peterson, MD, T.
Joseph Reeves, MD, David 0 . Williams, MD and William L.
Winters, Jr ., MD.
This document was reviewed by the officers and other
responsible individuals of the two organizations and re-
ceived final approval in March 1988. It is being published
simultaneously in Circulation and Journal of the American
0735-1097/88153 .30
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College of Cardiology. The potential impact of this docu-
meet on the practice of cardiology and some of its unavoid-
able shortcomings are clearly set out in the introduction .
Charles Fisch, MD, FACC
I. Introduction
The American College of Cardiology/American Heart
Association Task Force on Assessment of Diagnostic and
Therapeutic Cardiovascular Procedures was formed to make
recommendations regarding appropriate utilization of tech-
nology in the diagnosis and treatment of patients with
cardiovascular disease . Coronary angioplasty is one such
important technique . We are currently witnessing an ex-
traordinary expansion of the use of coronary angioplasty as
an alternative means of achieving myocardial revasculariza-
tion
. An estimated 133,000 angioplasty procedures were
performed in the United States in 1986, up from 32,300 in
1983 (I). Such growth is attributable not only to demon.
stoned clinical benefit but also to recent technical advances
that have led to improved techniques and higher success
rates . In turn, this has led to some broadening of the
indications for coronary angiography and . in some settings,
overuse of both coronary angiography and angioplasty has
been suggested
. Accordingly, it was recommended that this
Subcommittee review current indications and develop guide-
lines for the use of coronary angioplasty . In doing so. we
have proceeded on the premise that, because diagnostic
coronary angiography is essential for undertaking coronary
angioplasty, all of the indications and guidelines for prudent
coronary angiography, promulgated in an earlier ACC/AHA
Task Force report, have been met (2).
Because the technique of angioplasty is in evolution and
the intermediate-term results are not yet fully elucidated,
these recommendations are likely to change over the years .
This report is not intended to provide strict indications or
contraindications for the procedure because multiple varia-
bles must be weighed in selecting the individual for balloon
angioplasty treatment . These relevant considerations in-
clude occupational needs, the family setting, associated
illnesses and individual preferences concerning life style .
Rather, the report is intended to provide general guidelines
that may he helpful to the practitioner as well as to health
care administrators and other professionals interested in the
delivery of today's medical care . The American College of
Cardiology and the American Heart Association recognize
the fact that the ultimate judgment regarding the propriety of
any specific procedure is the responsibility of the physician
caring for the patient. The guidelines should not be consid-
ered all inclusive or exclusive of other methods that may be
available for the care of the individual patient . The Subcom-
mittee will not offer detailed recommendations concerning
the specific resources required to perform coronary angio-
plasty or to train individuals performing the procedure . It is
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essential that physicians performing angioplasty and other
related procedures arc adequately trained, that facilities and
equipment used are capable of obtaining the necessary
radiographic information and that the safety record of the
laboratory is acceptable. Some current thoughts related to
training, credentialing and facilities required to engage in
present day angioplasty are presented in Appendixes A and
B .
The format of this report includes some general consid-
erations that provide a brief historical review of the growth
and development of the procedure, identification of contrain-
dications to its use and a statement acknowledging general
risks associated with angioplasty . This is followed by a brief
discussion of considerations unique to angioplasty and in-
clude an enumeration of those factors currently recognized
as influencing a successful outcome, the requirement for
r argicat backup, angioplasty performed at the time of initial
catheterization, management of the patient after angioplasty,
the problems of restenosis and incomplete revascalarization
and the need for institutional mortality/morbidity review
committees . Lastly, specific guidelines for the application of
coronary angioplasty are presented; these have been devel-
oped according to anatomic (single versus maltivessel dis-
ease), clinical (asymptontatic versus symptomatic patients)
and physiologic (presence or absence of inducible ischemia)
considerations . Most importantly, the indications for angio-
plasty are judged categorically to be either class 1 .11 or 111 1,
based primarily on a multifactorial risk assessment weighed
against expected outcome. Also included are judgments of
feasibility, appropriateness to the clinical setting and overall
efficacy viewed in the light of present day knowledge and
technology.
Ii . General Considerations
A. Background
Symptomatic coronary artery disease is present in >6
million individuals in the United States . Despite the avail-
ability of effective medics) therapy, a significant proportion
of patients are candidates for a revascularization procedure
because of unacceptable symptoms or potentially life-
threatening lesions . An estimated 284,000 coronary artery
bypass operations were performed in 1996, no from 188,800
in 1983 ; similarly, coronary angioplasty procedures have
increased from 32,300 in 1983 to 133,000 in 1986 (I). Until
recently, angioplasty has been performed most often on
patients with single vessel coronary disease whereas coro-
nary byi:ass surgery now is used more often to treat multi-
vessel coronary disease, with the majority of patients cur-
rently receiving three or more bypass grafts . The use of
'Classes 1
.11 and Ill are Defined on pages 538 to
539 in section IV of this
repay .
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internal mammary artery grafting has risen dramatically in
recent years, from an estimated 6,000 procedures in 1983 to
67,000 in 1986 (1) . The leading indication for surgery contin-
ues to be the relief of angina, an approach supported by
findings of recent randomized trials that have shown that,
compared with medical therapy, surgical revascutarizatiun
significantly reduces symptoms and improves the quality of
life (3). At the same time there has been an expansion of the
subsets of patients in whom it is recognized that bypass
surgery improves survival
. This improvement in survival has
been established for patients with left main coronary artery
disease (>50% stenosis) (4) and certain patients with three
vessel coronary disease (5-7 ;. Additional information from
the Coronary Artery Surgery Study Registry would also
suggest that coronary bypass surgery improves survival in
patients with three vessel disease and normal ventricular
function if either severe symptoms exist or an exercise test is
positive for ischemia or chest pain (8,9)
B . Immediate and Long-Term Results
Coronary angioplasty was first introduced by Andreas
Gruentzig in September 1977 (10) as an alternative form of
revascutarization ; it thus constitutes a relatively new form of
therapy . During the early years of its application. Gruentzig
and others used coronary angioplasty predominantly to treat
patients with discrete, proximal
. noncalcified subtotal occlu-
sive lesions in a single coronary artery . In subsequent years
the technique has been applied successfully to patients with
muttivessel disease, multiple subtotal stenases in the same
vessel, accessible complete occlusions of recent vintage,
partial occlusion of saphencus vein or internal mammary
artery grafts and recent total thrombotic occlusions in acute
myocardial infarction, as well as to iaolaled high risk patients
with congestive heart failure and cardiogenic shock
.
By 1980 Gruenrzig had performed the procedure on 169
symptomatic patients, 4030 of whom had muttivessel dis-
ease. The follow-up of these patients now extends to as long
as to years and documents persistent long-term benefit with
only 5 cardiac deaths; 90 patients remain asymptontatic.
However, repeat angioplasty was regeired in 27 patients and
coronary bypass surgery in 19 (11)
.
NHLBI Registry. Because of the promising early clinical
experience, the National Heart, Lung, and Blood Institute
(NHLBI) established a Percutaneous Transluminal Coro-
nary Angioplasty (PTCA) Registry in 1979 to help evaluate
the technique. Through 1902, a total of 3,079 patients were
entered into the voluntary Registry and numerous analyses
from this data bank have substantiated the effectiveness and
safety of angioplasty i12) . As with any new procedure,
technical advances have resulted in improved success and
wider appticabiiiiy of the procedure . Prompted by these
changes, the National Heart, Lung, and Blood Institute
reopened the Registry is 1985 to evaluate more recent trends
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in angiaplasty
. Sixteen centers agreed to voluntarily collect
data on an additional 2.500 patients. These recent additions
to the Registry indicate that the immediate success rate
(defined as >20% change in tuminat diameter narrowing
without the occurrence of death, myocardial infarction or
bypass operation during hospitalization) increased to 78%
compared with 61% in the initial patient cohort (i3)
.
Despite
a recognized change in the case mix to more complex cases .
the rate of nonfatal myocardial infarction decreased front 4 .9
to 4 .3% and emergency coronary artery bypass graft surgery
from 5 .8 to 3.4%
; the mortality rate remained unchanged (1 .2
versus 1 .0%)
. Whereas only 25% of patients in the initial
Registry had multivesseldisease, 53% were so categorized in
the most recent Registry . This subgroup of patients in the
new Registry (that is, patients with muttivessel coronary
artery disease) hed an overall success rate of 73% . However.
when the data are analyzed for completeness of revascular-
ization, defined in the conventional manner as no residual
lesions of >50% narrowing, only one-third of the patients
qualified (14).
Such data must be viewed in the context that
balloon angioplasty is not currently undertaken when lesions
have 50 to 60% luminal diameter narrowing or when chronic
total occlusions are present
.
The long-term benefit of angioplasty has been examined
in the first FTCA Registry group for which >5 years of
follow-up are available (IS) . After hospital discharge the
annual mortality rate is low . approxinstely 1% per year, and
the rate of nonfatal myocardial infarction is also low at 2%
per year. Symptomatic improvement in the successful cases
was high with 70% of the patients pain-free at 4 years .
Freedom from major cardiac events (death . myocardial
infactian, need for bypass so . geryl over a 5 year period of
follow-up of a large series from one major center was
reported ro be 79% (16)
.
These data, although they do not
address the problem of resterrosis and arc derived from a
population in which 75% of the patients had single vessel
disease, do indicate that tong-term clinical benefit without
increased risk of death or myocardial infarction can be
expected after angioplasty . Follow-up information on pa-
tients exclusively with muttivessel disease is less complete .
Cowley et al. (17) reported initial success in 92% of patients
with muttivessel coronary artery disease . with 48% of the
patients asymptontatic and 82% symptomatically improved
al a mean foitow.up time of 24 months. A follow-up study of
605 patients undergoing angioplasty for multivessel disease
at Emery University demonstrated a 3 year freedom from
cardiac event rite of 83% (18). Preliminary findings in the
National Heart, Lung, and Blood Institute Registry indicate
a freedom from, death, myocardial infarction or surgery after
I year of follow-up in 75% of 402 patients with muttivessel
disease (19) . In these studies restenosiv with subsequent
hospitaliza-ior for redilation was not considered a cardiac
event but viewed as an integral part of the strategy of
angiaplasty.
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Comparison with bypass surgery. Whereas angioplasty
now is applied successfully to patients with multivessel
coronary artery disease (13,20), it must be viewed in com-
parison with coronary bypass surgery. The operative mor-
tality rate for patients undergoing elective bypass surgery
has steadily fallen and now approximates 2% in most centers
(21).
Although it is recognized that >50% of
bypass grafts
will occlude after 10 years (22), internal mammary artery
bypass grafts may provide a superior Conduit with improved
long-term patency. Indeed, recent studies (23) suggest that a
patency rate of >90e at IG years can be achieved . The
long-term clinical benefit of bypass surgery is well defined,
with a survival rate of 82% at 8 years for double vessel
disease and 79% for triple vessel disease as reported from
the Coronary Artery Surgery Study (24). Symptomatic im-
provement can be expected in 70% and asymptomatic status
in 50°k after 5 years . For patients who have received an
internal mammary artery graft to the left anterior descending
coronary artery, with or without associated vein grafts, there
is evidence of both improved sm rival and a reduction in
major cardiac events after 10 years of follow-up compared
with findings in patients who received vein grafts only (23).
Inherent differences exist between angioplasty and bypass
surgery. When successful, the former is less traumatic, less
costly and requires a shorter hospital stay than the latter .
However, bypass surgery is applicable to a wider group of
patients because dilation of longstanding total occlusions
and diffuse disease is often not possible with angioplasty .
Angioplasty, in certain instances, leaves patients with in-
complete revascularization, which understandably is a more
common phenomenon with increasing severity of disease
(14,25). There are those (26) who advocate a strategy of
"intentional" incomplete revascularization in some patients
with multivessel disease, and they report follow-up data
suggesting that these patients are no more symptomatic than
are individuals who have complete revascularization . Other
reports (25,27) on the long-term follow-up of patients with
multivessel disease indicate that those who have incomplete
revascularization after angioplasty are more symptomatic
than are those who have complete revascularization .
Restenoses. Angioplasty outcome is also complicated by
restenusis, the . phenomenon of renarrowing of the dilated
arterial segment within 8 months of the procedure . Sympto-
matic restenosis occurs in 20 to 25% of patients, whereas
angiographic studies suggest that the rate of restenusis is as
frequent as 30 to 35% (28,29) and may be as high as 45% for
lesions at the origin of the left anterior descending artery .
Preliminary studies in patients with multivessel disease
suggest that restenusis may also be more frequent as more
lesions are dilated (30). Experience indicates that restenosis
can be managed very successfully by repeat angioplasty (31) ;
however, the procedure exposes the patient to additional
morbidity, mortality and cost . Nevertheless, angioplasty is
initially less expensive and inherently less invasive than is
tACC V.I. 12, No. 2
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bypass surgery and is a more attractive alternative to many
patients because a rapid return u) normal functional status is
possible
.
C. Contraindications to Angioplasty
In general, the contraindications to angioplasty include all
of the relative contraindications enumerated for the perfor-
mance ofcoronary angiography as outlined In the guidelines
of
an earlier ACCIAHA report (2). Before undertaking
angioplasty it is imperative that the patient clearly under-
stand the procedure, its potential complications and the
alternatives of medical therapy or bypass surgery . Addition-
ally, the importance of
a relative contraindication to angio-
plasty will vary with the symptomatic state as well as the
general medical condition of the individual patient . Certain
risks may be appropriate in severely symptomatic individu-
als who, for example, are not candidates for bypass surgery,
whereas these risks would be inadvisable for an asympto-
matic or mildly symptomatic individual . With this caveat the
following are enumerated as generally accepted contraindi-
cations to the performance of angioplasty :
1 . Absolute contraindication:
a) There is no significant obstructing lesion.
b) Multivessel disease with severe diffuse atheroscle-
rosis is present for which an alternative form of
revascularization would be unequivocally more ef-
ficacious .
c) There is a significant obstruction (>50%) in the left
main coronary artery and this main segment is not
protected by at least one completely patent bypass
graft to the left anterior descending or left circum-
flex artery
.
d) There is no formal cardiac surgical program within
the institution .
2 . Relative contraindications:
a) A coagulopathy is present : Conditions associated
with bleeding abnormalities or hypercoaguable
states may be associated, respectively, with unac-
ceptable risks of serious bleeding or thrombotic
occlusion of a recently dilated vessel .
III There is no clinical evidence for spontaneous or
inducible myocardial ischemia .
c) In multivessel angioplasty, the patient's condition
is such that coronary occlusion resulting from any
one dilation could result in cardiogenic shock . This
group of patients is characterized, for example, by
patients who have large areas of myocardial dys-
function as a result of previous myocardial infarc-
tion and who have arteries with high grade lesions
whose acute occlusion would result in cumulative
damage equal to approximately 40 to 50% of the
total myocardium .
d) The anticipated su
•c
ess rate of dilation is low (for
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example, chronic total occlusions >3 months old or
subtotal lesions exceeding 20 mm in length)
.
e) The lesion under consideration is a borderline ste-
notic lesion (usually <60% stenosis). Such lesions
should not be dilated because of the demonstrated
risk of a restensetic lesion at the same site of even
greater severity. In some instances, objective evi-
dence of myocardial ischemia related to the lesion
can change the designation from a "borderline" to
a "significant" lesion that would
be appropriate far
dilation .
0 Variant or vasospastic angina is present in patients
with <60% stenoses.
g) The lesion under consideration is in a noninfarct-
related artery in patients with multiecsscl disease
who are undergoing cardiac catheterization during
the acute phase of myocardial infarction.
In addition to these generally accepted relative contrain-
dications, there are other conditions in which clinicians have
considerable reservation about the risk/benefit ratio of angio-
plasty. Over and above a fundamental risk of mortality and
morbidity there is the added dimension of risk of failure of
the procedure as a result of early closure as well as a
substantial risk of restenosis . The risks are viewed as a
continuum and it is their aggregate weight that should
ultimately determine whether a specific procedure should or
should not be undertaken (see section 111F).
D. Risks Associated With Angioplasty
Because coronary angioplasty requires visualization of
the coronary anatomy as well as systemic arterial and
venous access, patients undergoing the procedure are at risk
for the same potential complications that are known to be
associated with diagnostic cardiac catheterization . Included
are arterial or venous obstructions, vessel perforations,
bleeding, hypersensitivity reactions and infection . Myocar-
dial infarction, stroke and death can also occur as a result of
cardiac catheterization but are infrequent .
Specific complications can occur that are directly related
to the coronary angioplasty procedure . Balloon inflation
results in localized trauma to the coronary artery wall ; the
net result is usually atheroma fracture and arterial expansion
that produce an increase in the luminal area available for
blood transport
. At times, balloon inflation or guide wire or
catheter manipulation can cause more extensive arterial wall
damage with medial dissection and the creation of en occlu-
sive intimal flap . Thrombus formation also may occur at the
dilation site. Either of these two latter consequences can
exacerbate coronary narrowing and result in progression to
abrupt total coronary artery occlusion . In the absence of a
well developed collateral circulation, acute coronary occlu-
sion usually results in severe myocardial ischemia and
myocardial infarction that, if extensive or in the setting of
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preexisting impaired left ventricular systolic function, may
cause hemodynamic collapse and death . The most recent
data in the National Heart, Lung, and Blood Institute
Reg'stry (derived from very experienced centers) indicate
that the procedure is still associated with a 1% in-hospital
mortality rate and an incidence rate of non-fatal myocardial
infarction of approximately 4%, although the aced 'or emer-
gency bypass surgery has decreased to about 3 .5% (13). In a
recent study (12), investigators reported a death rate of 0 .2%
for patients undergoing elective angioplasty at two experi-
enced centers .
If coronary occlusion should occur, recrossing the oc-
cluded segment and repeating balloon inflation, inserting a
perfusion catheter or using thrombolytic or vasodilator
agents can, on occasion, reestablish coronary artery patency
and relieve ischemia . Prolonged maneuvers to this end are
discouraged because emergency surgical revascularization
may be delayed
. The use of intraaortic balloon ceunterpul-
sation in the setting of acute coronary occlusion may reduce
the magnitude of ischemia and augment systemic perfusion .
When needed, surgical revascularization should be under-
taken immediately because of known time limitations on
preserving ischemic myocardium . The probability of myo-
cardial infarction is high and mortality is increased when
coronary artery surgery is undertaken on an emergency
basis ; reports (33-35) indicate
a
25 to 40 incidence rate of
nonfaral new Q wave infarctions among patients undergoing
emergency surgery after a failed angioplasty .
Other infrequent complications unique to coronary angio-
plasty include intmcoronary embolization of atherosclerolic
or thrombotic material, coronary perforation, laceration or
rupture of a coronary artery with subsequent hemopericar-
dium and tamponade .
E. Need for Surgical Backup
An experienced cardiovascular surgical team should be
available within the institution' for emergency surgery for
all angioplasty procedures. The Subcommittee feels strongly
that there should be no exception to this requirement and
holds the position that all arrangements requiring the trans-
portation of patients to off site surgical facilities for such
emergency surgery fail to meet the necessary standards of
care exercised by prudent physicians and cannot be con-
doned
.
A formal surgical consultation for elective angioplasty
provides a means for a second opinion to the cardiologist,
"'Within the institution" is generally intended to mean within the same
hospital. In those instances in which two adjacent hospitals arc physically
connected such that emergency uanspon by stretcher or gumey can be
achieved rapidly and ed tively, the transport of patients between the two
hospitals for emergency cardiac surgical services would not
be viewed as "of
site ."
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the patient and the family, and represents the ideal approach
because it underscores the reality of potential, serious com-
plications and the need for a team approach . However, this
is often impractical, may introduce delay in the procedure
and lengthen the hospital stay . It is appropriate, however, to
obtain prior surgical and anesthesiology consultations on all
patients identified as being at high risk for abrupt vessel
closure as well as those patients judged to
be high risk
surgical candidates because of age, markedly impaired ven-
tricular function or associated medical disorders such as
chronic pulmonary disease, cerebrovascular disease and the
like . The exact arrangement for surgical standby will vary
from institution to institution depending on such obvious
factors as the number of operating rooms available for
cardiac surgery and the number of surgeons, perfusionists,
nurses and other personnel (35). The primary and essential
requirement is the capacity to provide rapid surgical support
when angioplasty fails
; otherwise, optimal patient care be-
comes seriously compromised .
On-going experience in large multicenter trials under.
scores the need for urgent revascularizalion by emergency
bypass surgery in the setting of both elective and emergency
angioplasty . Thus it is reaffirmed that all angioplasty proce-
dures should be undertaken only in institutions that have
formally approved cardiac surgical programs.
F. Need for Institutional Review
A rigorous mechanism of valid peer review must be
established and on-going within each institution performing
coronary angioplasty because 1) angioplasty is an interven-
tional procedure associated with known risks of serious
complications including death ; 2) it is a therapeutic modality
whose efficacy has a recognized association with operator
skill and experience; and 3) in certain instances, the proce-
dure can be viewed as a remunerative undertaking per-
formed by the same physician who initiates and interprets
the diagnostic studies leading to the procedure itself. In this
latter circumstance it is imperative that the responsible
physician arrange for a consulting opinion from an appropri-
ate specialist .
Although institutional review can take many forms and
will vary according to such factors as the size of institutions
and departments, the number of staff and the volume of
procedures, there are some basic requirements for such
review to be meaningful . At a minimum, the opportunity
must exist for cardiologists and cardiac surgeons knowledge-
able about the procedure to review the overall results of the
program on a regular basis. Specific attention should be
directed to success and failure rates and complications
leading to morbidity, including emergency surgical proce-
dures, and mortality. The review should also examine the
quality and accuracy of cinearteriographic studies and the
JACC Val . 12, No . 2
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appropriateness of indications and it should discuss con-
traindications .
The surgical profession has long since provided a work-
able model for addressing these and similar issues with
regularly scheduled mortality and morbidity conferences
that include appropriate committee (for example, tissue)
reports and impose attendance requirements that are de-
signed to assure impartial peer review. Institutions with
medical or surgical groups, or both, that cannot adequately
meet this obligation should undertake regional review with
cooperating institutions or abandon their program in angio-
plasty.
III. Specific Considerations
A . Successful Angioplasty and Its Determinants
A successful angioplasty procedure is defined as one in
which a o20% change in luminal diameter is achieved, with
thefinal diameterstenosis <
50% and without the occurrence
ofdeath, acute myocardial
infarction or the need for emer-
gency bypass operation . Atherosclerotic coronary stenoses
are considered significant if they have the potential of
impairing coronary blood flow under physiologic circum-
stances. Experimental data indicate that coronary flow re-
serve declines as coronary diameter is reduced beyond 50% .
It is acknowledged that the visual assessment of coronary
narrowing on cineangiograms is associated with substantial
interobserver and intraobserver variability. Determination
of coronary narrowing by caliper techniques is a readily
available methodology that correlates closely with sophisti-
cated computer quantitative methods. For the purpose of
this report, a significant stenoses is defined as one that
results in a 50% reduction in coronary diameter as deter
mined by caliper method .
After a decade of experience it is now reasonable to
expect an overall success rate of zg5% for single lesion
dilations within any angioplasty program . This same ex-
perience further indicates that, in addition to operator
experience, procedural success relates to certain patient
characteristics and, very importantly, to angiographic char-
acteristics of the lesion or lesions to be dilated .
Patient-related factors influencing a successful dilation
are primarily age (<65 years) and gender (male), but clinical
variables such as a history of hypertension, diabetes, prior
myocardial infarction, prior bypass surgery and impairment
of left ventricular function are known to be associated with
procedural mortality.
Angiographic patterns outlining the morphologic charac-
teristics of vessels and defining lesion-specific characteris-
tics have now been identified that greatly influence the
likelihood of a successful dilation . Recognizing the uniquely
technical aspects of angioplasty and in an attempt to risk
stratify any given procedure, the Subcommittee proposes
the following lesion-specific classification as a guide for
JACC Vol. 12, No.2
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estimating the likelihood of a successful procedure as well as
the likelihood of developing abrupt vessel closure (see also
Table l, section IV):
Type A lesions
These are lesions in which the anticipated success rate
should be ?85% and the risk of abrupt vessel closure is
low because they are discrete, concentric lesions and
demonstrate all of the following characteristics: ready
accessibility, location in a nonangulated segment (<45°),
smoothness of contour, little or no calcification, absence
of total occlusion, nonostial location, absence of major
branch involvement, absence of thrombus .
Type B Lesions
These are lesions in which the anticipated success rate
ranges from 60 to 85% or the risk of abrupt vessel closure
is moderate, or both . They include all lesions that vre
neither type A nor type C (see later) and they are usually
identified by such characteristics as, but not Railed to,
the following: tubular shape, eccentricity, vccessibility
influenced by moderate tortuosity of proximal segment,
location in a moderately angulated segment (>45', <90°),
irregularity of contour, moderate or sevetc calcification,
presence of thrombus . ostial location, bifurcation lesions
requiring double guide wires, total occlusions <3 months
old . It is recognized that lesions with these characteris-
tics, although associated with some increase in 9brnpt
vessel closure, may in certain instances be associated
with a comparatively low likelihood of a major complica-
tion
. This is often the case, for example, in unsuccessful
attempts to dilate total occlusions that are <3 months old
or in the dilation of some type B lesions in which the
distal vessel is supplied by abundant cotlaterals .
Type C lesions
These are lesions in which the anticipated success rate
is <60% or the risk of abrupt vessel closure is high, or
both, because they demonstrate any of the following
characteristics
: diffuse disease (>2 cm in length), exces-
sive tortuosity of proximal segments, location in an
extremely angulated segment (>90°), total occlusion >3
months old, inability to protect major side branches,
degeneration of older vein grafts with friable lesions
.
Attempts to dilate such lesions should not be undertaken
when they are present in vessels supplying lar bre or
moderate areas of viable myocardium .
B
. Angioplasty at the Time of Initial Cardiac
Catheterization
The selection of patients for angioplasty demands careful
review of the clinical and anatomic features of each case.
This is optimally done after diagnostic cardiac catheteriza-
tion when unhurried review of the cineangiograms can take
place (in consultation with colleagues when necessary) to
determine the appropriateness of the case and plan a dilation
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strategy . In addition, the patient, family and
referring
phy-
sician can be consulted, the therapeutic options reviewed
and the risks and benefits of the procedure discussed before
obtaining informed consent . This process obviously subjects
the patient to a repeat catheterization with its inherent risks
and recognized morbidity, adds additional days of hospital-
ization, introduces delay in the patient's return to work and
normal physical activities and clearly adds to the total direct
and indirect costs involved . These disadvantages are coun-
terbalanced by the overriding benefits of a careful preangio-
plasty evaluation, improved patient preparedness and, in
many instances, more timely arrangement for surgical
backup and scheduling . It
: particular, the evaluation of the
cororar anatomy is often the most difficult aspect in the
selection of patients for angioplasty
; decisions made on the
basis of
video images can be inaccurate and can lead to
increased risk for the patent . For these reasons, it is
recommended that angioplasty not be performed routinely as
an extension of an initial diagnostic catheterization .
There are, however, well defined subsets of patients for
whom it is appropriate to contemplate performing angio-
plasty at the time of the initial diagnostic cardiac catheter-
ization. This group would include patients with unstable
angina who cannot be discharged from the hospital without a
revascularization procedure and who are suspected of hav-
ing single vessel coronary disease on the basis of age,
absence of prior myocardial infarction of known coronary
disease and recent onset of symptoms. Because a high
proportion of these patients have single vessel disease ame-
nable to angioplasty, it is reasonable to prepare the patient
for this possibility before diagnostic cardiac catheterization
by obtaining informed consent and a complete preangio-
plasty evaluation. Similarly, individuals who have had prior
angioplasty and are undergoing catheterizaton to evaluate
the possibility of restenosis represent a group of patients
whose coronary anatomy is generally known in advance and
whose clinical management is facilitated by performing
angioplasty immediately after the diagnostic study when
indicated . In selected patients with acute myocardial infarc-
tion in whom adequate reperfusion is not obtained by
thrombolytic therapy, angioplasty may be of benefit . In
such patients when multivessel disease is present, only
the vessel related to the area of infarction should be di-
lated . If angioplasty is to be considered in lieu of throm-
bolytic therapy, it is recommended that the procedure be
applied to patients who present within 4 h of the onset of
symptoms unless there is strong evidence for ongoing ische-
mia . Whatever the clinical circumstances, it is imperative
that high quality fluoroscopic and video replay images or
promptly developed tine films be available before undertak-
ing angioplasty at the time of initial diagnostic catheteriza-
tion.
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C. Postangioplasty Management
Immediately after coronary angioplasty attention is di-
rected to monitoring for evidence of recurrent ischemia and
to assure appropriate hemostasis at the site of catheter
insertion . Specific protocols for sheath removal, continua-
tion of anticoagulation and antiplatelet therapy will
vary
from institution to institution . Ordinarily, heparin anticoag-
ulation used during the procedure is not reversed with
protamine for fear of inducing thrombosis at sites of balloon
inflation. When angioplasty is performed percutaneously,
the indwelling vascular sheaths usually can be removed
within 3 to 4 h after the last bolus injection of heparin . In
certain instances, such as the setting of extensive intimal
disruption, thrombus formation or embolization, a constant
infusion of heparin may be des ired . Sheaths are then re-
moved after the termination of the heparin infusion or after
temporary cessation of therapy .
A small proportion of patients in whom angioplasty was
judged angiographically successful will experience symp-
toms of myocardial ischemia during this observation period
after the procedure . If electrocardiographic (ECG) abnor-
malities suggesting ischemia are detected there is a substan-
tial risk of abrupt vessel closure, which has been associated
with a comparatively high mortality rate (10 to 12%) (36). An
individualized judgment must be made as to whether addi-
tional angioplasty, emergency bypass surgery or continued
medical therapy is appropriate . Accordingly, the equipment
and services required to perform repeat angiography and, if
necessary, repeat angioplasty, need to be available 24 h a
day in institutions that undertake a program in angioplasty .
Patients should be instructed about risk factor modifica-
tion before hospital discharge . Depending on the individual
case, this advice would include hypertension control, diabe-
tes management, serum lipid reduction, abstinence from
tobacco, weight control and timing of the return to full
activity. Patients should be informed of the importance of
contacting their physicians if symptoms recur .
D . Restenosis
Although the initial outcome for coronary angioplasty
procedures has improved progressively over the last 10
years (reaching primary success rates in native coronary
arteries as high as 90 to 95% in well chosen patients), the
incidence of restenosis over the first 6 to 8 months after
dilation has remained unchanged at approximately 30%. The
rate of restenosis in native arteries depends partly on its
definition ; in the National Heart, Lung, and Blood Institute
Registry, restenosis was defined as a loss of 50% of the gain
achieved in luminal diameter at the time of the successful
angioplasty, or a 30% increase in narrowing at the site of
stenosis (28) . Follow-up of 557 patients undergoing repeat
coronary angiography, indicated that restenosis was associ-
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ated with the recurrence of symptoms in the ntgjority of
patients ; likewise, relatively few patients with single vessel
disease harbora clinically silent restenosis . The rate of silent
restenosis was 14% in the National Heart, Lung, and Blood
Institute Registry, and a 4% rate was reported in a combined
study from the Cardiology Branch of the National Heart,
Lung, and Blood Institute and Georgetown University
(28,37). On the basis of multivariate analysis, independent
factors that predispose to restenosis Include angioplasty in
the left anterior descending coronary artery, absence of
intimal dissection immediately after angioplasty, residual
gradient after dilation >15 mm Hg, a large residual stenosis
after angioplasty, and unstable angina (29) . Univariate anal-
ysis has pointed to several other risk factors for restenosis,
including male gender, diabetes mellitus, patients with
chronic total occlusions, thrombus, an initial transstenotic
gradient >40 mm Hg and recent, as opposed to long-
standing, occurrence of angina . In addition, several centers
have reported (38) that lesions that involve the origin of a
vessel or its branch points are more prone to restenosis .
Factors that have not been correlated with risk of restenosis
include age, functional class, history of previous myocardial
infarction, hypertension, history of smoking, serum choles-
terol, presence of calcification at the site of dilation, mor-
phologic features of the lesion, lesion length, inflation pres-
sure and medications on discharge
.
Patients who develop clinical or angiographic evidence,
or both, of restenosis in native coronary arteries are readily
treated with a second dilation procedure . For repeat angio-
plasty, the primary success rate is higher than for the initial
procedure (85 versus 63% in the National Heart, Lung, and
Blood Institute Registry), a relatively low myocardial infarc-
tion rate of 1 .5%, and a reduced incidence of complete
occlusion with need for emergent coronary artery bypass
graft surgery (2 versus 3.5%).
A significantly higher restenosis rate of 50
17s is noted
when coronary angioplasty is performed in the proximal
anastomosis or body of a saphenous vein bypass graft . By
contrast, dilations performed in the distal graf lartery anas-
tomotic site exhibit restenosis rates comparable with those
of native vessel sites .
E . Incomplete Revascularization
As coronary angioplasty is being utilized in ever more
complex clinical and pathoanatomic situations, concern is
now expressed that patients are being subjected to "incom-
plete revascularization" or less than optimal correction of
their pathophysiologic state . in patients with multivessel
disease, some operators attempt to dilate all accessible,
significant lesions whereas others approach only the lesion
deemed most likely to cause myocardial ischemia (the so-
called culprit lesion)
. The surgical experience is relatively
convincing that "complete revascularization," that is, graft
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insertion around all moderate to severe coronary stenoses,
leads to a superior therapeutic result . Follow-up studies (39)
of patients with surgical revascularization suggest that com-
plete revascularization not only relieves signs and symptoms
of myocardial ischemia, but also it is more effective than
incomplete revascularization in protecting against future
coronary events .
During surgery, partial or incomplete revascularization
usually results from the extent or distribution of a patient's
coronary artery disease and less often is a reflection of the
skills and diligence of the surgical team . In patients under-
going angioplasty, partial revascularization is likely to occur
for several reasons in addition to the extent and distribution
of coronary disease and the extent of myocardial fibrosis .
Quite clearly it also relates to the specific anatomy that
determines the accessibility of lesions for angioplasty . The
occurence of restenosis in one or more of .he dilated lesions
also may result in the development of partial revasculariza-
tion. Although early graft closure after bypass surgery also
converts complete to partial revascularization, this is a less
common phenomenon than restenosis after arterial dilatior .
At present, partial revascularization after coronary angio-
plasty is an inherent limitation of the procedure and can be
expected to occur frequently in patients undergoing multi-
vessel angioplasty. Notwithstanding, the advocates of angio-
plasty in patients with multivessel disease point to the
successful relief of symptoms and the elimination of objec-
tive signs of ischemia after stress tests in a high percentage
of such patients in whom all lesions cannot be successfully
dilated . Moreover, the claim is made that angioplasty palli-
ates the disease process and often allows a period of clinical
temporizing before surgical revascularization is required.
Angioplasty also allows for a strategy of performing the
dilation procedure on successive days or weeks
. Multiple
successive interventions are feasible and, although there is
some degree of cumulative risk, angioplasty differs in this
regard from aortocoronary bypass graft surgery, in which
the opportunity for serial repeat thoracotomies is under-
standably more limited .
There has not been sufficient accumulation of clinical
experience, either retrospectively or prospectively, to judge
the relative advantage of angioplasty versus aortocoronary
bypass graft surgery for relief of signs and symptoms of
myocardial ischemia and infarction in multivessel disease.
The adequacy of myocardial revascularization by angio-
plasty, particularly in comparison with that provided by
surgery, will require randomized prospective studies in
which coronary pathoanatomic subsets are closely matched .
The National Heart, Lung, and Blood Institute has funded
two such studies to date
: one at Emory University that
began in July 1987 and the multicenter BARI Trial (Bypass
Angioplasty Revascularization Investigation) that began in
the fall of 1987 . Also of importance will be the long-term
follow-up of large numbers of patients treated by these two
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competing interventions with matched cohorts compared by
multivariate analysis,
F
. Cumulative Consequences of Failed
Angioplasty
Inherent to the strategy of coronary angioplasty is the
"price of failure." This is more than the risk of a serious
complication and embraces the consideration that 5 to 15%
of these procedures will be initially unsuccessful and that 3
to 6% of patients will require urgent or emergent surgery to
bypass a coronary artery occluded during the procedure .
Furthermore, approximately 30% of the patients who have
an initially successful procedure will develop restenosis of
the dilated segment within 8 months and will require a
second angioplasty or bypass surgery . Thus, there are a
number of patients in whom the risk relative to the cost and
morbidity associated with angioplasty as a primary therapy
may be considerably higher than that of some patients who
are treated from the outset with revascularization surgery
.
These consequences of early failure must be considered
in clinical decision making and in evaluating the relative
merits of bypass surgery versus coronary angioplasty in a
given patient . Although there is little specific information on
the price of failure in patients with multivessel angioplasty, it
is likely that it is higher than for single vessel angioplasty and
indeed there will be categories of patients in whom multi.
vessel angioplasty is not prudent .
IV . Indications for Angioplasty
Preamble
The approach to every angioplasty procedure requires a
knowledgeable judgment that weighs the likelihood of a
successful Procedure* against the likelihood of failure and
the risk of complications (abrupt vessel closure, morbidity,
mortality and restenosis) . In attempting to prioritize indica-
tions for angioplasty, the Subcommittee was greatly intlu-
enced by the specific considerations discussed in section III :
t) factors favoring a successful dilation; 2) factors associated
with abrupt vessel closure ; 3) restenosis ; 4) incomplete
revascularization ; and 5) the consequences of failure of the
procedure.
Experience to date suggests that the factors favoring a
successful procedure are age <65 years, male gender, single
vessel disease, single lesion angioplasty, subtotal occlu-
sions, absence of calcification, accessibility of the lesion and
normal ventricular function. Counterbalancing these varia-
bles that support the likelihood of successful angioplasty are
'A successful procedure is defined mans in which a .20% change in
luminal diameler is achieved with the final dianxter stenosis <55%, without
the occurrence of death, acme myaasdial infarction or bypass
Operation
doting he,pilaheulion .
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Table 1. Characteristics of Type A, B and C Lesions
•
	
Discrete i<10 mm length)
Concentric
• Readily accessible
• Nonengulated segment, <45'
• Smooth contour
• Tabular (101 . 20 mm length)
• Eccentric
• Moderate lanumily of proximal segment
•
Moderately angulated segment, >45', <90'
	 Irregelarcontour
•
DiBpse (>2 em lorgih)
•
Excessive lonaosily of proximal segment
•
Extremely angulated segment
>90'
the preprocedural factors that favor abrupt vessel closure
during or shortly after angioplasty, These are viewed as
being female gender, length of lesion, eccentric lesions,
bifurcation/side branch lesions, angulation of the segment
being dilated, other stenoses in the same vessel and the
presence of thrombus (40) .
The clinical variables that have been associated with
increased procedural mortality are currently identified as age
>65 years, female gender, a history of hypertension, diabe-
tes, prior myocardial infarction, prior bypass surgery, mul-
tivessel disease, left main coronary disease, a large area of
myocardium at risk, impairment of left ventricular function
and collateral vessels that supply significant areas of myo-
cardium and originate distal to the segment to be dilated (32) .
The factors associated with restenosis are currently rec-
ognized as recent onset of angina (<3 months), unstable
angina, variant angina, diabetes mellitus, multivessel dis-
ease, right ostial lesions, lesions located at the origin of the
left anterior descending coronary artery, lesions in the
proximal anastomoses or body of a vein graft, chronic total
occlusions, presence of thrombus, severity of residual lesion
(>30%) and a significant residual gradient (>15 to 20 mm
Hg) (28,29) .
Both clinical judgment and statistical estimates permit
appropriate weighting and integration of these variables to
formulate likelihood estimates (high, moderate or low) for
any given procedure according to
1. the likelihood of a successful dilation,
2. the likelihood of abrupt vessel closure with subsequent
morbidity and mortality, and
Lesion-specific Chsratteristies
Type A Lesions (high success, >95%: low risk)
• Little or no calcification
•
Less than totally occlusive
• Not meet in location
• No major branch involvement
• Absencr of thrombus
Type a Lesions (moderate success, 601085% ; moderate risk)
Type C Lesions (low suwese
.
<60% ;
high risk)
• Moderate to heavy calcification
• Total occ:usons <3 months old
•
Ostial in location
•
Bifurcation esions requiring double guide wires
• Some thrombus present
• Total occlusion >3 months old
•
Inability to protect major side bmnches
• Degeeetated vein areas with friable lesions
'Although the risk of abrupt vessel closure is moderate, in entrain instances the likelihood of e maim,
complicalion maybe Iowa in dilation of totalecclueicex <t months old or when abundant collateral channels supply
the distal vessel .
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3 . the likelihood of restenosis .
Although operator experience and individual patient
characteristics are important factors relating to outcome,
both procedural success and the development of abrupt
vessel closure are largely determined by specific character-
istics of the vessels and lesions involved . Recognizing the
unique technical aspects of angioplasty and with the objec-
tive of fostering knowledgeable judgments about risk strati-
fication, the Subcommittee has summarized three types of
lesion-specific characteristics based on the current state of
knowledge in Table I (see also section 1II-A) .
Type A lesions have those characteristics that allow an
anticipated success rate of =_85% and have a low risk of
abrupt vessel closure .
Type B lesions have those characteristics that result in a
lower than optimal success rate ranging from 60 to 85% or
have a moderate risk of abrupt vessel closure, or both.
Type C lesions have those characteristics that result in an
unacceptably low success rate (<60%) or have a high risk of
abrupt closure, or both .
It is recognized that we are dealing with a discipline of
cardiovascular care that is undergoing considerable growth
and development; as new insights are gained we can antici-
pate further refinement of the guidelines for coronary angio-
plasty that are set forth in this document using the following
classification :
Class I: Conditions for which there is general agreement
that coronary angioplasty is justified . A class I indication
should not be taken to mean that coronary angioplasty is the
only acceptable therapy .
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Class II : Conditions for which coronary angioplasty is
performed but there is divergence of opinion with respect to
its justification in terms of value and appropriateness.
Class III : Conditions for which there is general agree-
ment that coronary angioplasty is not ordinarily indicated .
1 . Single Vessel Coronary Artery Disease
A . Asymptomatic or Mildly
Sympturnatie (functional class 1)
Patients With or Without Medical Therapy. Symptoms
Are Defined in Accordance With the Canadian Cardio.
vascular Society Cletsjfication (Appendix C)
Class I
This category applies to patients who have a signifi-
cant lesion* in a major epicardial artery that subtends a
large area of viable myocardium and who
I. show evidence of severe
myocardial ischemia while
on medical therapy during laboratory testing, i .e .,
ischemia induced by low level exercise and mani-
fested by
a) rat man of ischemic ST segment depression in
multiple leads, or
b) reversible thallium perfusion defects in more
than one vascular region, or
c) exercise-induced reduction in the ejection frac-
tion or wall motion abnormalities an radionu-
elide ventriculographic studies, or both, or
2. have been resuscitated from cardiac arrest or from
sustained ventricular tachycardia in the absence of
acute myocardial infarction, or
3
. must undergo high risk noacardiac surgery, such as
repair of an aortic aneurysm, iliofemoral bypass or
carotid artery surgery, if angina is present or there
is objective evidence of ischemia, or
4 . have a history of myocardial infarction together
with a history of hypertension and ischemic ST
segment depression on the baseline ECG .
All of these patients should
•
	
have one or more type A lesions in the same vessel or
its branches and
• be in the low risk group for morbidity (abrupt vessel
closure <4%) and mortality (<0.5%) .
Class II (mild or no symptoms, single vessel coronary
disease)
This category applies to patients who have a significant
lesion in a major epicardial artery that subtends at least a
moderate-sized area of viable myocardium and who
1
. show objective evidence of myocardial ischemiat
r
-For the purpose of Ibis report, a significant stuvasis is defined m one that
esults in a 50% reduction in coronary diameter as determined by caliper
method.
tEvidence of myocardial ischemia during laboratory testing is taken to
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while on medical therapy during laboratory testing,
and
a) have ar least a moderate likelihood of successful
dilation, and
b) have a low risk of abrupt vessel closure, and
c) are in the low risk group for morbidity and
mortality .
Cla_
., III (mild or
no symptoms, single vessel coronary
disease)
This category applies to all other patients with single
vessel disease and mild or no symptoms who do not fulfiltthe
preceding criteria for class I or class 11 . It includes, for
example, patients who
I . have only a small area of viable myocardium at
risk, or
2 . do not manifest evidence of myocardial iscbemia
during laboratory testing, or
3 . have borderline lesions of <50% diameter reduc-
tion, or
4 . have type C lesions, or
5 . are in the moderate or high risk group for morbidity
and mortality .
Comments. In some patients, circumstances of occupa-
tion or employment may result in a class H indication being
viewed as a class I category. Such patients would include
individuals whose occupation involves the safety of others
(airline pilots, bus drivers, track drivers, air traffic control-
lers, for example) and those in certain oecupatiohs that
frequently require sudden vigorous activity (fire fighters,
police officers, athletes, for example) . However, class III
indications for asymptomatic or mildly symptomatic individ-
uais with si gle vessel disease pertain to a risk profile that
precludes the patient's suitability as a class I or 11 indication .
B . Symptomatic Patients With Angina Pectoris (functional
classes If to IV, unstable angina) With Medical Therapy
and Single Vessel Disease
Class I
This category applies to patients who have a significant
lesion in a major epicardial artery that subtends at least a
moderate-sized area of viable myocardium and who
1 . show evidence of myocardial ischemia while on
medical therapy during laboratory testing (in-
cluding ECG monitoring at rest), or
2. have angina pectoris that has proved inadequately
responsive to medical treatment . "Inadequately
mean exercise-induced ischemia (with or without exercise-induced angina
pectoris) manifested by al mar of ischemic ST ses neat depression a one or
e-indaced reversible
thallium
perfusion defects and/or exercise-
induced reduction in the ejection fraction and/or wall main abnormalities cm
radionuclide vearioulographic studies .
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responsive" is taken to mean that patient and
physician agree that angina significantly interferes
with the padsnt'  occupation or ability to perform
his or her usual activities, or
3 . are intolerant of medical therapy because of uncon-
trollable side effects .
All of these patients should
• have at least a moderate likelihood of successful dila-
tion and
• be in the low risk group for morbidity and mortality .
Qass If (syr;, ;domatic, single vessel coronary disease)
This category applies to patients who have a significant
lesion in a major epicardial artery that subtends at least a
moderate-sized area of viable myocardium and who
1 . show evidence of myocardial ischemia while on
medical therapy during laboratory testing (in-
cluding ECG monitoring at rest, and
a) have one or more type B lesions in the same
vessel or its branches, or
b) are in the moderate risk group for morbidity
(abrupt vessel closure <8%) and mortality
(<1%), or
2. have disabling symptoms and a small area of viable
myocardium at risk, and
a) at least a moderate likelihood of successful
dilation, and
b) are in the low risk group for morbidity and
mortality, or
3. despite significant angina do not have objective
evidence of myocardial ischemia while on medical
therapy during laboratory testing, and
a) have at least a mod^.rate likelihood of successful
dilation, and
b) are in the low risk group for morbidity and
mortality .
Class III (symptomatic, single vessel, coronary disease)
This category applies to all other symptomatic patients
with single vessel disease who do not fulfill the preceding
criteria for class I or class 11 . It includes, for example,
patients who
1 . have only a small area of viable myocardium at risk
in the absence of disabling symptoms, or
2. have clinical symptoms not likely indicative of
ischemia, or
3. have Type C lesions, or
4. are in the high risk group for morbidity and mortal-
ity
.
Comments. Patients with single vessel disease who have
significant symptoms constitute one of the largest groups of
patients undergoing angioplasty. However, the generally
excellent prognosis far patients with single vessel disease
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should be a paramount consideration before undertaking an
interventional procedure in these patients . It is imperative
that there be some assurance that the significant symptoms
are indeed due to the coronary lesion proposed for dilation .
Although significant symptoms may justify a lower tolerance
for the risk of abrupt vessel closure or subsequent resten-
osis, one cannot compromise on the risk for significant
mortality or morbidity.
l!. Multivessel Coronary Artery Disease
A. Asymptomade orMiWy Symptomotie (lancrionol clan 1)
Patients With or Without Medical Therapy
Class I
This category applies to patients who have one significant
lesion in a major epicardial artery that could result in nearly
complete revascularization because the additional lesion(s)
subtends a small viable or nonviable area of myocardium .
Additionally, patients in this category must
I . have a large area of viable myocardium at risk, and
2 . show evidence of severe myocardial ischemia while
on medical therapy during laboratory testing, or
3 . have been resuscitated from cardiac arrest or from
sustained ventricular tachycardia in the absence of
acute myocardial infarction, or
4. be undergoing high risk noncardiac surgery and
demonstrate objective evidence of ischemia, or
5. have a history of myocardial
infarction
together
with a history of hypertension and ST segment
depression on the baseline ECG.
All of these patients should
• have one or more type A lesions whose successful
dilation would provide relief to all major regions of
ischemia, and
• be in the low risk group for morbidity and mortality
.
Class II (mild to no symptoms, multivessel coronary disease)
This category applies to patients who
1 . are similar to patients in class I but who
a) have a moderate-sized area of viable myocar-
dium at risk, or
b) have objective evidence of myocardial ischemia
while on medical therapy, or
2. have significant lesions in two or more major epi-
cardial arteries, each of which subtends at least a
moderate-sized area of viable myocardium .
All of these patients should
• show evidence of myocardial ischemia while on medical
therapy during laboratory testing, and
• have one or more type A or B lesions whose successful
dilation would provide relief to all major regions of
ischemia, and
• be in the low risk group for morbidity and mortality .
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Class III (mild to no symptoms, multivessel disease)
This category applies to all other patients with multives-
sel disease and mild or no symptoms who do not fulfill the
above criteria for class I or class II
. It includes, for example,
patients who
I . have only a small area of viable myocardium at
risk, or
2. have a subtotally occluded vessel requiring angio-
plasty wherein the development of total occlusion
of the vessel would result in severe hemodynamic
collapse due to left ventricular dysfunction, or
3. have more than two major arteries with type B
lesions, or
4
. have type C lesions in major epicardial vessels
serving moderate or large areas of viable myocar-
dium, or
5 . are in the moderate or high risk group for morbidity
or mortality (for example, advanced left ventricular
dysfunction rejection fraction <2t%] in the absence
of angina or evidence of ischemia) .
B. Symptomatic Patients With Angina Pectoris (functional
classes II to IV, unstable angina) With Medical Therapy
and Multivesset Disease
Class I
This category applies to patients who have significant le-
sions in each of two major epicardial arteries both subtending
at least moderate-sized areas of viable myocardium and who:
1 . show evidence of myocardial ischemia while on
medical therapy during laboratory testing (in-
cluding ECG monitoring at rest), or
2. have angina pectoris that has proved inadequately
responsive to medical therapy, or
3. are intolerant of medical therapy because of uncon-
trollable side effects .
All of these patients should :
• have type A and B lesions whose successful dilation
would provide relief of all major regions of ischemia,
and
a be in the low risk group for morbidity and mortality .
Class II (symptomatic, multivessel disease)
This category applies to patients who have significant
lesions in two or more major epicardial arteries that subtend
at least moderate-sized areas of viable myocardium and who
l . are similar to patients in class I but who are in the
moderate risk group for morbidity and mortality, or
2 . have angina pectoris but do not necessarily have
objective evidence of myocardial ischemia while on
medical therapy during laboratory testing .
All of these patients should
• have type A and B lesions whose successful dilation
would provide relief of all major regions of ischemia,
and
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• be in the moderate risk group for morbidity and mor-
tality
3 . have disabling angina that has proved inadequately
responsive to medical therapy, and
a) be considered a poor candidate for surgery be-
cause of advanced physiologic age or coexisting
medical disorders, and
b) have one or more type A and B lesions that
cannot be successfully dilated, and
c) be in the moderate risk group for morbidity and
mortality.
Class III (symptomatle, multive sel coronary, disease)
This category applies to all other symptomatic patients
with multivessel disease who do not fulfill the preceding
criteria in class I or class 11
. It includes, for example,
rave sts who
l . have only a small area of myocardium at risk in the
absence of disabling symptoms, or
2. have a subtotally occluded vessel requiring angio-
plasty wherein the development of total occlusion
of the vessel would result in severe hemodynamic
collapse due to left ventricular dysfunction,
or
3. have type C lesions in major epicardial vessels
serving moderate or large areas of viable myocar-
dium, or
4 . are in the high risk group for morbidity or mortality,
or both.
Comments . It is to be stressed that risk assessment is
different in patients with mulhvessel as compared with single
vessel disease . In t. a former there ideally should be the
opportunity for anatimically complete revascularization,
although it is recognize:
: loot adequate functional revasen-
larization can be achieved without necessarily being anatom-
ically
complete . In every instance the goal is to achieve relief
of ischemia at a risk acceptable for the procedure . In
estimating this risk in multivessel disease it is imperative that
each lesion be considered in the context of all other lesions
prrscnt. Some assessment must then be made of the conse-
quences likely to ensue should any one of the attempted
dilations fail and result in abrupt vessel closure . For exam-
ple, it would be judged inappropriate to attempt dilation
of a
proximal high grade left anterior descending artery lesion if
that vessel was supplying many collateral vessels to a large
area of viable myocardium in the distribution of a totally
occluded dominant right coronary artery .
III . Acute Myocardial Infarction (Angioplasty
During Initial Hospitalization)
Class I
This category applies to the dilation ofa significant lesion,
in the infarct-related artery only, in patients who
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1 . have recurrent episodes of ischemic chest pain
particularly if accompanied by ECG changes
(postinfarction angina), or
2 . show evidence of severe myocardial ischerniawhile
on medical therapy during laboratory testing per-
formed before hospital discharge, or
3 . have recurrent ventricular tachycardia or ventricu-
lar fibrillation, or both, while on intensive anti-
arrythmic therapy.
All of these patients should :
• have one or more type A lesions and
• be in the low risk group for morbidity and mortality .
Class II
This category applies to the dilation of significant lesions
in patients who
I
. are similar to patients in class I but who
a) have type B lesions, or
b) undergo multivessel angioplasty, or
c) are in the moderate risk group for morbidity or
mortality, or both, or
2. are within the very early hours of an evolving
myocardial infarction, with or without thrombolytic
therapy, or
3. are within 12 h of the onset of cardiogenic shock or,
in those who have survived cardiogenic shock, in
the period before discharge, or
4. are asymptomatic and have a significant residual
lesion in the infarct-related artery after thromboly-
tic therapy, or
5 . show objective evidence of myocardial ischemia
dodgyg laboratory testing performed before dis-
charge, or
6. have had a non-Q wave myocardial infarction, and
a) have single vessel disease with
b) type A lesions, and
c) are in the low risk group for morbidity and
mortality .
Class 111
This category applies to all other patients in the immedi-
ate postinfarction period (during initial hospitalization) who
do not fulfill the preceding criteria for class I and class II .
For example:
I . undertaking dilation of additional lesions in a vessel
other than the infarct related artery within the early
hours of infarction (0 to 6 h), or
2 . dilation of residual lesions that are borderline (50 to
60% diameter reduction), or
3 . dilation of type C lesions, or
4. undertaking angioplasty in patients in the high risk
group for morbidity and mortality .
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Comments
. The role of angioplasty in the management of
patients during the course of an acute myocardial infarction
is currently the subject of intense investigation. Although
there is evidence that the procedure can be used effectively
as a primary means of establishing reperfusion in the very
early hours of an evolving infaretion(41,42), many imp( rtant
questions remain unresolved such as the impact of 1-oce-
dural delay required to undertake angioplasty, the influence
of thrombus on abrupt vessel closure and subsequent resten-
osis.
The use of angioplasty in conjunction with thrombolytic
therapy is of particular interest and is thought by many to
hold great promise . A note of caution is warranted, however,
in light of the findings of three separate large randomized
trials (43-45) that have recently reported adverse effects
when angioplasty was performed immediately, rather than
later, after the administration of tissue plasminogen activa-
tor. The optimal timing and long-term benefit of angioplasty
in the management of patients with acute infarction are
questions that must await further data .
APPENDIX A
Training and Credentialing
It is generally acknowledged that specialized skills are
required for coronary interventional techniques. Training in
these procedures necessitates thorough skills in diagnostic
and therapeutic cardiology and particularly cardiac catheter-
ization and angiography
. Whereas the majority of individuals
currently performing angioplasty learned the technique by
observing experts and attending "how-to" seminars, the
complexity of the procedure and the recognized need for
hands-on experience dictate that formal training programs in
angioplasty become the required means of learning . En-
trance requirements to such programs should follow the
completion of a structured cardiology fellowship training
program as outlined in the guidelines set forth in the Be ,
thesda Conference on Adult Cardiology Training (J Am Coll
Cardiol 1986:7
:1205-6) .
There is a growing consensus within the cardiology
community that, for the individual who plans to perform
coronary angioplasty, an additional year of training beyond 3
years of fellowship training that includes extensive experi-
ence with angiography, is required . A suggested minimum of
125 coronary angioplasty procedures, including 75 per-
formed as the primary operator, has been recommended as
the experience required to develop the appropriate skill and
judgment. Equally important is the demonstration of contin-
ued experience on the completion of a formal training
program. A minimal case load for a single physician is
estimated to be about one case per week . Continued perfor-
mance of angioplasty should be dependent on the demon-
stration of success and complication rates that meet ex-
JACC Val. 12, No .2
August lout529-45
peeled standards . Regular attendance at major angioplasty
postgraduate courses would provide continuing education in
newer angioplasty techniques and equipment .
Alternate routes of training for established angiographers
should be developed. Individualized training programs that
provide an extensive, primary operator experience can equip
such an angiographer to perform angioplasty expertly . In
this setting, the quality and manner of the direct supervision
are of greater importance than the absolute number of cases
to be performed in this "tutorial" setting . In general, it is
believed that such a training experience should include
involvement in no less than 50 cases .
The physicians with appropriate training and demon-
strated competence in the performance of angioplasty are
those who should receive proper credenlialing to perform
angioplasty in hospitals . It is recognized that hospitals are
currently under intense pressure to grant privileges to car-
diologists who have not had adequate training so as to
protect the hospitals' referral base. This practice should rot
be condoned ; rather, the responsible leadership of institu-
tions offering coronary angioplasty as part of their health
care program should insist on the documentation of accred-
ited training and the maintenance of skills of its approved
operators by some reasonable standard of practice .
In the present climate it should be clear that not every
cardiologist desiring to perform angioplasty should perform
the procedure. Similarly, not every institution anxious to
offer the procedure as part of its health care program can be
allowed to do so. A significant volume of cases per institu-
tion and per operator is essential for the maintenance of
assured quality and safe care . It is the strong sense of this
Subcommittee that these issues should not be resolved in the
marketplace but within the structure of organized medicine .
Formal credentialing should quickly be put into place and
the oversight of the operational aspects and maintenance of
skills should fall within the province of organized cardiology .
It would seem that existing national organizations have both
the resources and the manpower to meet this major obliga-
tion in a prompt and effective manner . The hospital industry
must likewise alter its current practices regarding this spe-
cific form of high technology care. Success, failure, death
and morbidity mandate some form of regionalization and
centraiization of resources . To accomplish this mission in a
responsible fashion, a deregulated industry must, in short
order, demonstrate that it can accomplish this stated mission
by its own sense of community responsibility, or it should
give way to state and federal regulation .
APPENDIX B
Requisite Facilities for Coronary Angioplasty
The rate of growth for coronary angioplasty within the
United States over the past decade has clearly had an impact
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on the need for well equipped, well staffed cardiac
catheterization laboratories .
The minimal requirements for facilities in any hospital
where coronary angioplasty is to be performed are
1 . A cardiac laboratory that is well equipped with a
physiologic recording system, a high resolution fluo-
roscopic and cineangiographic X-ray unit, full emer-
gency resuscitation equipment including circulatory
assist devices and a full complement of drugs for
treatment of myocardial ischemia or infarction, or
both;
2 . A surgical operating suite that is equipped to provide
general anesthesia and extracorporeal circulation and
has a full complement of instruments for thoracic and
cardiac surgery and a full complement of drugs used
for management of the cardiac patient .
The optimal resources for a cardiac catheterization and
radiographic facility have been carefully and exhaustively
detailed in "Optimal Resources For Examination Of The
Heart And Lungs: Cardiac Catheterizatioa And Radio-
graphic Facilities" (Circulation 1983 ;68 :893A-930A). This
report sets guidelines for administration, space, equipment,
personnel and working arrangements for diagnostic cardio-
vascular laboratories . Basically all of the recommendations
set forth in that document apply to any laboratory planning
to perform angioplasty procedures .
In addition, however, it is recommended that a laboratory
performing coronary angioplasty have available the follow-
ing:
I . An ample inventory of balloon dilation catheters rang-
ing from 2.0 to 4.0 mm, a complete range of existing
guide wires of variable flexibility and steerability and
two or more calibrated balloon inflation devices .
2. A high resolution fluoroscopic system and an optimal
TV chain that allows ready visualization of a 0 .014
inch guide wire and where still frames or "road map
images" can be displayed simultaneously with the real
time fluoroscopic image.
3. Either biplane fluoroscopic capability or preferably an
angulating X-ray tube image intensifier arm that allows
ready three-dimensional determination of the ana-
tomic position of a guide wire or balloon catheter .
4. Radiation exposure control systems that would in-
clude such items as
an X-ray beam with automatic
collirlatiolt, a carbon fiber scattered radiation grid,
carbon fiber table top and a correct tube filter . Further
reduction of radiation exposure to personnel can be
achieved by gap filling during cinematography, using a
reference monitor for path finding and video discs for
automatic storage and replay . All personnel should be
further protected from radiation exposure by the use
of appropriate lead aprons, eyeglasses, thyroid protec-
tion and additional shielding of the X-ray tube
.
5 . The specific requisite space, equipment, personnel and
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administration of a cardiac surgery operating suite
have been outlined previously in dstait by the later-
society Commission for Heart Disease Resources (Cir-
culation 1975 ;52 :A23-41) .
APPENDIX C
Grading of Angina of Effort by the Canadian
Cardiovascular Society*
1 . "Ordinary physical activity does not cause . . . .
angina," such as walking and climbing stairs
. Angina
with strenuous or rapid or prolonged exertion at
work or recreation.
II .
"Slight limitation
of ordinary activity ." Walking or
climbing stairs rapidly, walking uphill, walking or
stair climbing after meals, or in cold, or in wind, or
under emotional stress, or only during the few hours
after awakening . Walking more than 2 blocks on the
level and climbing more than one flight
of ordinary
stairs at a normal pace and in normal conditions .
Ill . "Marked limitation of ordinary physical activity ."
Walking one to two blacks on the level and climbing
one flight of stairs in normal conditions and at normal
pace.
IV. "Inability to carry
on any
physical activity without
discomfort-anginal syndrome
may be present at
rest ."
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